Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742986 · ClinicalTrials.gov registry record · Phase 2
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03742986: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT03742986 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742986, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
Primary Outcome
pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0).
Interventions
- DRUG Nivolumab 360mg
- DRUG Paclitaxel 80mg/m^2
- DRUG Doxorubicin 60mg/m^2
- DRUG Cyclophosphamide 600mg/m^2
- DRUG Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 2 |
What the finished NCT03742986 record still lists
NCT03742986 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Nivolumab 360mg is the first listed.
NCT03742986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03742986 about?
NCT03742986 is a clinical study titled "Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)". Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
What is the current status of trial NCT03742986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2019-05-02. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT03742986?
The interventions under investigation include: Nivolumab 360mg (DRUG), Paclitaxel 80mg/m^2 (DRUG), Doxorubicin 60mg/m^2 (DRUG), Cyclophosphamide 600mg/m^2 (DRUG), Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT03742986?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03742986's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI